Revenue (Quarterly)

Revenue: The sum of all revenue fields included for a company's operating activities.

Xeris Biopharma Holdings, Inc. (XERS) had Revenue of $92.10M for the most recently reported fiscal quarter, ending 2026-06-30.

Quarterly Annual

Figures for fiscal quarter ending 2026-06-30

Income Statement Financials
Revenue	$92.10M
Net Income	$-31.10M
Cost of Goods Sold	$12.51M
Gross Profit	$79.59M
Operating Expenses	$86.93M
Operating Income	$5.17M
Non-Operating Income/Expense	$-36.27M
Pre-Tax Income	$-31.10M
Normalized Pre-Tax Income	$-31.10M
Income after Taxes	$-31.10M
Income from Continuous Operations	$-31.10M
Consolidated Net Income/Loss	$-31.10M
Normalized Income after Taxes	$-31.10M
EBIT	$5.17M
EBITDA	$9.29M
Weighted-Average Shares Outstanding (Basic)	172.82M
Weighted-Average Shares Outstanding (Diluted)	172.82M
Earnings per Share (EPS) (Basic)	$-0.18
Earnings per Share (EPS) (Diluted)	$-0.18
Balance Sheet Financials
Current Assets	$274.76M
Property, Plant, and Equipment	$4.83M
Long-Term Assets	$137.15M
Total Assets	$411.90M
Current Liabilities	$189.57M
Long-Term Debt	$188.81M
Long-Term Liabilities	$232.07M
Total Liabilities	$421.64M
Common Equity	$-9.73M
Tangible Shareholders Equity	$-115.25M
Shareholders Equity	$-9.73M
Common Shares Outstanding	173.59M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$18.13M
Cash Flow from Investing Activities	$-0.53M
Cash Flow from Financial Activities	$-6.89M
Beginning Cash	$115.06M
End Cash	$125.77M
Increase/Decrease in Cash	$10.71M
Stock-Based Compensation	$15.21M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	1.45
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	1.05
Debt to Equity Ratio	-25.95
Gross Margin	86.41%
Operating Margin	5.62%
EBIT Margin	5.62%
EBITDA Margin	--
Pre-Tax Profit Margin	-33.77%
Profit Margin	-33.77%
Free Cash Flow	$17.60M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.22
Inventory Turnover	0.15
Receiveable Turnover	1.59
Days Sales in Receivables	56.78
Return on Equity	319.51%
Return on Tangible Equity	26.99%
Return on Assets	-7.55%
Return on Investments	-17.37%
Book Value Per Share	$-0.06
Free Cash Flow per Share	$0.10
Operating Cash Flow per Share	$0.10

Data from Zacks Investment Research, Inc.